新闻盘点数据库 - 内部版
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
Financing(1:投融资;2:合作)
Contributor
TitleLink
Therapeutic Area
DiseasesHot AreaStageDesignationCompanyCity/StateCountry
Financing(for Yechen)
2
3
4
5
6
7
8
9
10
11
6/22/2018
New study supports long-dismissed idea: Herpes viruses could play role in Alzheimer’s
https://www.statnews.com/2018/06/21/herpes-viruses-alzheimers-disease-role/
12
6/22/2018Targeting cancer cells' escape vehicles to stop tumor metastasis
https://www.fiercebiotech.com/research/targeting-a-protein-key-exosome-production-to-stop-cancer-growth
13
6/22/2018
U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden ≥10 mut/Mb
https://news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-fda-accepts-application-opdivo
14
6/22/2018
Stocks Rocket More than 50% at Nanobiotix’s Sarcoma Drug Phase II/III Trial Data
https://www.biospace.com/article/stocks-rocket-more-than-50-percent-at-nanobiotix-s-sarcoma-drug-phase-ii-iii-trial-data/
15
6/22/2018
Researchers Make Possible Link Between Alzheimer’s and Herpes Virus
https://www.biospace.com/article/researchers-make-possible-link-between-alzheimer-s-and-herpes-virus/
16
6/21/2018
New study supports long-dismissed idea: Herpes viruses could play role in Alzheimer’s
https://www.statnews.com/2018/06/21/herpes-viruses-alzheimers-disease-role/
17
6/21/2018
Shire Announces FDA Approval for Label Expansion of CINRYZE® (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients
https://www.shire.com/en/newsroom/2018/june/7rr5re
18
6/21/2018
New insight into how an old TB vaccine lowers blood sugar in Type 1 diabetes
https://www.fiercebiotech.com/research/new-insight-into-how-old-tb-vaccine-lowers-blood-sugar-type-1-diabetes
19
6/21/2018Cancer researchers target the dormant cells that seed tumours
https://www.nature.com/articles/d41586-018-05445-x
20
6/21/2018
Diabetes defeated by diet: How new fresh-food prescriptions are beating pricey drugs
https://www.cnbc.com/2018/06/20/diabetes-defeated-by-diet-new-fresh-food-prescriptions-beat-drugs.html
diabetes
21
6/21/2018
UPDATED: Six biotechs crowd into Nasdaq, raising $568M as the IPO party continues to lure companies to Wall Street
https://endpts.com/five-biotechs-crowd-into-nasdaq-raising-462m-as-the-ipo-party-continues-to-lure-companies-to-wall-street/
22
6/21/2018
Voyager Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for VY-AADC for the Treatment of Parkinson’s Disease
https://www.biospace.com/article/fda-grants-rmat-designation-to-voyager-therapeutics-vy-aadc-for-parkinson-s-disease/
23
6/21/2018
Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease
https://www.biospace.com/article/releases/incyte-announces-reach1-pivotal-trial-meets-primary-endpoint-of-overall-response-rate-for-ruxolitinib-jakafi-in-steroid-refractory-acute-graft-versus-host-disease/
24
6/21/2018
Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
https://www.biospace.com/article/releases/heron-announces-positive-topline-results-from-phase-2b-clinical-studies-of-htx-011-in-total-knee-arthroplasty-and-breast-augmentation/
25
6/21/2018
Novo Nordisk’s Semaglutide Shows Non-Inferiority Against 2 More Diabetes Competitors
https://www.biospace.com/article/novo-nordisk-s-semaglutide-shows-non-inferiority-against-2-more-diabetes-competitors/
diabetes
26
6/21/2018A Look at 6—Count ‘em, 6!—Biotech IPOs This Week
https://www.biospace.com/article/a-look-at-6-count-em-6-biotech-ipos-this-week/
27
6/20/2018
Decibel Hauls in $55M to Bring Multiple Hearing Drugs to the Clinic
https://www.xconomy.com/boston/2018/06/19/decibel-hauls-in-55m-to-bring-multiple-hearing-drugs-to-the-clinic/
28
6/20/2018Novimmune, TG ally to take CD47-CD19 bispecific into clinic
https://www.fiercebiotech.com/novimmune-tg-ally-to-take-cd47-cd19-bispecific-into-clinic
cancer
29
6/20/2018
With an AstraZeneca cancer drug in one hand, $37M in the other, Shanghai’s Alpha Bio zooms into a PhII study
https://endpts.com/with-an-astrazeneca-cancer-drug-in-one-hand-37m-in-the-other-alpha-bio-zooms-into-a-phii-study/
30
6/20/2018
Kallyope and Novo Nordisk Announce Collaboration to Discover Novel Therapeutics for Obesity and Diabetes
https://www.prnewswire.com/news-releases/kallyope-and-novo-nordisk-announce-collaboration-to-discover-novel-therapeutics-for-obesity-and-diabetes-300667999.html
31
6/20/2018
Apollo Endosurgery, Inc. Announces Pricing of $20.6 Million Public Offering of Common Stock
https://www.biospace.com/article/releases/apollo-endosurgery-inc-announces-pricing-of-20-6-million-public-offering-of-common-stock/
32
6/20/2018
Aaptiv Closes Series C with $52m raised to date; Amazon Alexa Fund and Warner Music Group among new investors
https://www.biospace.com/article/releases/aaptiv-closes-series-c-with-52m-raised-to-date-amazon-alexa-fund-and-warner-music-group-among-new-investors/
33
6/20/2018iTeos Therapeutics Closes on $75 Million Series B Financing
https://www.biospace.com/article/iteos-therapeutics-closes-on-75-million-series-b-financing/
34
6/19/2018
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases
http://www.mrknewsroom.com/news-release/vaccine-news/fda-grants-priority-review-mercks-supplemental-biologics-license-applicati
cancer
35
6/19/2018Startup aims to make allies of human gut’s microbes
https://www.bostonglobe.com/business/2018/06/18/microbiome/4qkHpemmUCWcNVO1ERuIyH/story.html
36
6/19/2018Google Is Training Machines to Predict When a Patient Will Die
https://www.bloomberg.com/news/articles/2018-06-18/google-is-training-machines-to-predict-when-a-patient-will-die
37
6/19/2018
Mega-money biotech round spills $116M into gene therapy upstart Freeline
https://endpts.com/mega-money-biotech-round-spills-116m-into-gene-therapy-upstart-freeline/
38
6/19/2018
Sarepta leads off Duchenne MD gene therapy study with a ‘home run’ on efficacy — but can they deliver in 2 years?
https://endpts.com/sarepta-leads-off-duchenne-md-gene-therapy-study-with-a-home-run-on-efficacy-but-can-they-deliver-in-2-years/
39
6/19/2018
Bay Labs’ EchoMD AutoEF Software Receives FDA Clearance for Fully Automated AI Echocardiogram Analysis
https://www.biospace.com/article/releases/bay-labs-echomd-autoef-software-receives-fda-clearance-for-fully-automated-ai-echocardiogram-analysis/
40
6/19/2018
Organ-on-a-Chip Company Emulate Closes on $36 Million Series C Financing
https://www.biospace.com/article/organ-on-a-chip-company-emulate-closes-on-36-million-series-c-financing/
41
6/19/2018
Roche Acquires Remaining Shares of Foundation Medicine for $2.4 Billion
https://www.biospace.com/article/roche-acquires-remaining-shares-of-foundation-medicine-for-2-4-billion/
cancer
42
6/19/2018
Chinese Biotechs Flex Financial Muscles With Continued Investments
https://www.biospace.com/article/chinese-biotechs-flex-financial-muscles-with-continued-investments/
43
6/18/2018
Solid Bio is back in business after the FDA lifts clinical hold on Duchenne MD gene therapy
https://endpts.com/solid-bio-is-back-in-business-after-the-fda-lifts-clinical-hold-on-duchenne-md-gene-therapy/
gene
44
6/18/2018
High-profile Chinese investor Vincent Cheung plays a lead role in raising $100M round for a Boston start-up
https://endpts.com/high-profile-chinese-investor-plays-a-lead-role-in-raising-100m-round-for-a-boston-start-up/
45
6/18/2018
Stealth BioTherapeutics Announces $100M Financings to Advance Clinical Development of Elamipretide and Pipeline
https://www.biospace.com/article/releases/stealth-biotherapeutics-announces-100m-financings-to-advance-clinical-development-of-elamipretide-and-pipeline/
46
6/18/2018Embodied Raises $22 Million in Series A
https://www.biospace.com/article/releases/embodied-raises-22-million-in-series-a/
47
6/18/2018
Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML
https://www.biospace.com/article/phase-iii-study-shows-quizartinib-prolongs-overall-survival-for-patients-with-deadly-type-of-relapsed-or-refractory-aml-/
cancer
48
6/18/2018
Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
https://www.biospace.com/article/releases/clover-biopharmaceuticals-doses-first-patient-in-australia-in-phase-i-study-of-scb-313-for-malignant-ascites/
49
6/18/2018
BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients
https://www.biospace.com/article/releases/biolinerx-presents-new-overall-survival-data-from-phase-2a-study-for-bl-8040-in-r-r-aml-patients/
cancer
50
6/18/2018
Cytokinetics’ Spinal Muscular Atrophy Drug Shows Promise in Phase II
https://www.biospace.com/article/cytokinetics-spinal-muscular-atrophy-drug-shows-promise-in-phase-ii/
gene
51
6/18/2018WindMIL Therapeutics Raises $32.53 Million
https://www.biospace.com/article/windmil-therapeutics-raises-32-53-million-in-series-b-financing/
52
6/18/2018
ObsEva Therapeutic Shows Reduction of Pain in Mid-Stage Endometriosis Trial
https://www.biospace.com/article/obseva-therapeutic-shows-reduction-of-pain-in-mid-stage-endometriosis-trial/
53
6/15/2018
Verrica Pharma bankrolls PhIII with a $75M IPO raise for lead skin drug
https://endpts.com/verrica-pharma-preps-for-phiii-with-a-scaled-down-75m-ipo-raise-for-lead-skin-drug/
54
6/15/2018Motif Completes Rolling NDA for Iclaprim
https://www.biospace.com/article/motif-completes-rolling-nda-for-iclaprim/
55
6/15/2018
Selecta Unveils Expanded Positive Clinical Data for its Gout Treatment
https://www.biospace.com/article/selecta-unveils-expanded-positive-clinical-data-for-its-gout-treatment/
56
6/15/2018
As Treatments Await FDA Ruling, Researchers Discover ‘Key Players’ in Early-Onset Parkinson’s Disease
https://www.biospace.com/article/as-treatments-await-fda-ruling-researchers-discover-key-players-in-early-onset-parkinson-s-disease/
CNS
57
6/15/2018
bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association
https://www.businesswire.com/news/home/20180615005159/en/
gene
58
6/14/2018
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
http://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-treatment-refract
cancer
59
6/14/2018
iiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine-demonstrating-the-ability-to-control-hiv-with-a-two-drug-regimen-in-treatment-na%C3%AFve-patients/
60
6/14/2018
Nightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia
https://globenewswire.com/news-release/2018/06/14/1524448/0/en/Nightstar-Therapeutics-Receives-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-NSR-REP1-in-Choroideremia.html
61
6/14/2018
Researchers outline another big disease target for Novartis’ canakinumab as drug slashes rate of gout flares
https://endpts.com/researchers-outline-another-big-disease-target-for-novartis-canakinumab-as-drug-slashes-rate-of-gout-flares/
62
6/14/2018
Mindstrong Health Announces $15M Series B Round Financing and Business Update
https://www.biospace.com/article/releases/mindstrong-health-announces-15m-series-b-round-financing-and-business-update/
CNS
63
6/14/2018
Pharnext Announces PXT3003 was Granted Priority Review by the China Food and Drug Administration
https://www.biospace.com/article/releases/pharnext-announces-pxt3003-was-granted-priority-review-by-the-china-food-and-drug-administration/
64
6/14/2018
Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of Two Global Studies in Progressive MS
https://www.biospace.com/article/releases/genentech-announces-new-ocrevus-ocrelizumab-data-on-long-term-disability-benefits-in-primary-progressive-multiple-sclerosis-and-initiation-of-two-global-studies-in-progressive-ms/
CNS
65
6/14/2018
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia
https://www.biospace.com/article/sage-therapeutics-forges-575-million-deal-with-shionogi-to-market-depression-drug-in-parts-of-asia/
66
6/14/2018
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
https://www.nature.com/articles/s41598-018-27264-w
67
6/13/2018Helping to End Addiction Over the Long-term
https://jamanetwork.com/journals/jama/fullarticle/2684941
68
6/13/2018
Alcohol-Addiction Drug Seems to Help Retroviral Compliance and Suppress HIV Levels
https://www.biospace.com/article/alcohol-addiction-drug-seems-to-help-retroviral-compliance-and-suppress-hiv-levels/
69
6/13/2018
Eisai Plans Invests $100M in Genetics Guided Dementia Discovery Facility in Cambridge, Mass.
https://www.biospace.com/article/eisai-plans-invests-100-million-in-genetics-guided-dementia-discovery-facility-in-cambridge-mass-/
70
6/12/2018
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)
https://www.businesswire.com/news/home/20180612006423/en/FDA-Approves-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Previously-Treated
cancer
71
6/12/2018
Galmed's 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study
https://www.prnewswire.com/news-releases/galmeds-600-mg-aramchol-achieved-a-regulatory-approvable-endpoint-showing-nash-resolution-without-worsening-of-fibrosis-in-nash-patients-in-the-global-phase-2b-arrest-52-week-study-300664733.html
Liver
72
6/12/2018
GenSight Biologics Reports Positive Additional Data from REVERSE Phase III Clinical Trial of GS010 for Treatment of Leber Hereditary Optic Neuropathy (LHON)
https://www.biospace.com/article/releases/gensight-biologics-reports-positive-additional-data-from-reverse-phase-iii-clinical-trial-of-gs010-for-treatment-of-leber-hereditary-optic-neuropathy-lhon-/
gene
73
6/12/2018
Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell
https://www.biospace.com/article/releases/agenus-discovery-enhances-activity-of-cancer-fighting-antibodies-findings-published-in-cancer-cell/
cancer
74
6/12/2018
FDA Grants Rare Pediatric Disease Designation to Albireo’s Liver Disease Drug
https://www.biospace.com/article/fda-grants-rare-pediatric-disease-designation-to-albireo-s-liver-disease-drug/
75
6/12/2018
Novartis Pays Regenxbio $100 Million for Gene Therapy Technology Under AveXis License Agreement
https://www.biospace.com/article/novartis-pays-regenxbio-100-million-for-gene-therapy-technology-under-avexis-license-agreement/
76
6/12/2018
Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting
https://www.businesswire.com/news/home/20180612005398/en/Sage-Announces-Pivotal-Phase-3-Trial-Status
CNS
77
6/11/2018Juvenescence Raises $50 Million in Series A Financing
https://www.biospace.com/article/releases/juvenescence-raises-50-million-in-series-a-financing/
78
6/11/2018
Surgical.AI Completes $20-Million Investment in caresyntax, raising caresyntax's Total First Round Financing to $31.9 Million
https://www.biospace.com/article/releases/surgical-ai-completes-20-million-investment-in-caresyntax-raising-caresyntax-s-total-first-round-financing-to-31-9-million/
79
6/11/2018
FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label
https://www.biospace.com/article/releases/fda-approves-addition-of-positive-overall-survival-data-from-phase-3-aspire-trial-to-kyprolis-carfilzomib-label/
80
6/11/2018
Allergan’s Atogepant Hits the Mark in Phase IIb/III Episodic Migraine Trial
https://www.biospace.com/article/allergan-s-atogepant-hits-the-mark-in-phase-iib-iii-episodic-migraine-trial/
CNS
81
6/11/2018
Translate Bio and Sanofi Ink Potential $850 Million mRNA Vaccine Development Deal
https://www.biospace.com/article/translate-bio-and-sanofi-ink-potential-850-million-mrna-vaccine-development-deal/
82
6/11/2018Melinta Therapeutics Snags $123 Million in a Public Offering
https://www.biospace.com/article/melinta-therapeutics-snags-123-million-in-a-public-offering/
83
6/8/2018FDA Approves Genentech’s Rituxan for Rare Skin Disease
https://www.biospace.com/article/fda-approves-genentech-s-rituxan-for-rare-skin-disease/
84
6/8/2018
Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
https://www.gene.com/media/press-releases/14728/2018-06-08/genentech-announces-fda-approval-for-ven
cancer
85
6/8/2018
New ‘genetic atlas’ of plasma proteins could unveil potential drug targets
https://www.fiercebiotech.com/research/new-genetic-atlas-plasma-proteins-could-unveil-potential-drug-targets
86
6/8/2018
Hydrogel could enable pancreatic islet transplants for diabetes
https://www.fiercebiotech.com/research/hydrogel-helps-avoid-immune-rejection-pancreatic-islet-transplants
87
6/7/2018
U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
https://finance.yahoo.com/news/u-fda-european-medicines-agency-120000225.html
cancer
88
6/7/2018KaNDy Therapeutics Announces Positive Clinical Data with Lead Candidate NT-814 for the Treatment of Symptoms of the Menopause
https://www.biospace.com/article/releases/kandy-therapeutics-announces-positive-clinical-data-with-lead-candidate-nt-814-for-the-treatment-of-symptoms-of-the-menopause/
89
6/7/2018
J&J, BOSTON U PARTNER TO MAP EARLY DETECTION BIOMARKERS FOR LUNG CANCER
https://www.biocentury.com/bc-extra/company-news/2018-06-06/jj-boston-u-partner-map-early-detection-biomarkers-lung-cancer
90
6/7/2018
Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania
http://investors.ophthotech.com/news-releases/news-release-details/ophthotech-enters-gene-therapy-agreements-university-florida-and
91
6/7/20184D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours
https://www.biospace.com/article/releases/4d-pharma-plc-enters-into-clinical-collaboration-agreement-with-msd-investigating-the-combination-of-keytruda-pembrolizumab-and-mrx0518-in-patients-with-solid-tumours/
92
6/7/2018
Could an old Amgen-developed RA drug make CAR-T treatments safer?
https://www.fiercebiotech.com/research/could-old-amgen-developed-ra-drug-make-car-t-treatments-safer
93
6/7/2018
Tilting at vaccines giants, SutroVax fuels up on a $170M-plus quest to vault past the world’s best-selling vaccine
https://endpts.com/tilting-at-vaccines-giants-sutrovax-fuels-up-on-a-170m-plus-quest-to-vault-past-the-worlds-best-selling-vaccine/
94
6/7/2018Biogen inks $357M option deal for TMS’ stroke drug
https://www.fiercebiotech.com/biotech/biogen-inks-357m-option-deal-for-tms-stroke-drug
95
6/6/2018
Genentech dives deeper into the microbiome, inking $534M deal with Microbiotica to develop IBD meds
https://endpts.com/genentech-dives-deeper-into-the-microbiome-inking-534m-deal-with-microbiotica-to-develop-ibd-meds/
96
6/6/2018
Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX’s door with an IPO application
https://endpts.com/eyeing-nda-for-its-diabetes-drug-hua-medicine-knocks-at-hkexs-door-with-an-ipo-application/
97
6/6/2018Axovant Licenses Gene Therapy for Parkinson’s Disease from Oxford BioMedica
https://www.biospace.com/article/axovant-licenses-gene-therapy-for-parkinson-s-disease-from-oxford-biomedica/
98
6/6/2018
Kite’s TCR cell therapy offers promise for HPV-positive solid tumors
http://insights.bio/cell-and-gene-therapy-insights/2018/06/06/kites-tcr-cell-therapy-offers-promise-for-hpv-positive-solid-tumors/
cancer
99
6/6/2018
Rich Heyman’s Metacrine tacks on another $65M to tackle a superior NASH drug
https://endpts.com/rich-heymans-metacrine-tacks-on-another-65m-to-tackle-a-superior-nash-drug/
100
6/6/2018
Tricida files for $150M IPO to fund kidney disease drug approval
https://www.fiercebiotech.com/biotech/tricida-files-for-150m-ipo-to-fund-kidney-disease-drug-approval
Loading...
 
 
 
癌症/综合
李阳选题
新靶点数据库
人工智能
微生物组
抗衰老
CRISPR
华人成就
 
 
Main menu